TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03687957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: -Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: -Standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: -Standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: -Standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: -Standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: -Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: * Week 1 (prior to the 1st dose of rhIL-7-hyFc)~* Week 2 (one week after rhIL-7-hyFc)~* Week 3 (two weeks after rhIL-7-hyFc)~* Week 4 (three weeks after rhIL-7-hyFc)~* Week 13 (prior to the 2nd dose of rhIL-7-hyFc)~* Week 14 (one week after rhIL-7-hyFc)~* Week 16 (three weeks after rhIL-7-hyFc) - optional~* Week 45 (eight weeks after the last dose of rhIL-7-hyFC)~* If ADA or NADA is observed in week 45, additional blood collections will be required every 2 months in order to monitor ADA/NADA levels until it decreases to the basal level~* At the time of tumor progression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: * Week 1 (prior to the 1st dose of rhIL-7-hyFc)~* Week 2 (one week after rhIL-7-hyFc)~* Week 3 (two weeks after rhIL-7-hyFc)~* Week 4 (three weeks after rhIL-7-hyFc)~* Week 13 (prior to the 2nd dose of rhIL-7-hyFc)~* Week 14 (one week after rhIL-7-hyFc)~* Week 16 (three weeks after rhIL-7-hyFc) - optional~* Week 45 (eight weeks after the last dose of rhIL-7-hyFC)~* If ADA or NADA is observed in week 45, additional blood collections will be required every 2 months in order to monitor ADA/NADA levels until it decreases to the basal level~* At the time of tumor progression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: * Week 1 (prior to the 1st dose of rhIL-7-hyFc)~* Week 2 (one week after rhIL-7-hyFc)~* Week 3 (two weeks after rhIL-7-hyFc)~* Week 4 (three weeks after rhIL-7-hyFc)~* Week 13 (prior to the 2nd dose of rhIL-7-hyFc)~* Week 14 (one week after rhIL-7-hyFc)~* Week 16 (three weeks after rhIL-7-hyFc) - optional~* Week 45 (eight weeks after the last dose of rhIL-7-hyFC)~* If ADA or NADA is observed in week 45, additional blood collections will be required every 2 months in order to monitor ADA/NADA levels until it decreases to the basal level~* At the time of tumor progression
Study: NCT01928394

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Study: NCT04069468

Intervention type: DEVICE
Intervention: TheraSphere
Description: Participants will receive treatment with TheraSphere in accordance with Instructions for Use
Study: NCT02034149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer-assisted management
Description: The peer-assisted management group received similar program for 3 months, the peer oriented group activities followed, including group discussions to share experience and sports map etc.
Study: NCT03126409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No-Touch vein harvesting technique
Description: The No-Touch technique focuses on saphenous vein graft harvesting, featured by preserving the surrounding tissue of the vein while at the same time avoiding manual distension.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional vein harvesting
Description: During saphenous vein harvesting, surrounding tissue of the vein is stripped off, and manual distension is routinely performed
Study: NCT04175886

Intervention type: DRUG
Intervention: Tofacitinib
Description: Patients will be treated with tofacitinib
Study: NCT05575895

Intervention type: DIETARY_SUPPLEMENT
Intervention: Ingestion of the energy drink (Red Bull®)
Description: Ingestion of 250 ml of the energy drink (Red Bull®)

Intervention type: DIETARY_SUPPLEMENT
Intervention: Ingestion of mineral water
Description: Ingestion of 250 ml of mineral water (Minalba®)
Study: NCT01359371

Intervention type: BEHAVIORAL
Intervention: Peer telephone cessation counseling
Description: For Veterans who received the inpatient Tobacco Tactics intervention, trained volunteers initiated follow-up telephone cessation counseling at 2, 14, 21 and 60 days after in-patient discharge; three attempts were made per time point.
Study: NCT01156116

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP mask
Description: The subjects who are randomized to CPAP treatment will undergo an overnight CPAP titration in the laboratory, which will be performed manually by a registered technician according to American Academy of Sleep Medicine (AASM) guidelines .Subjects will be admitted in the early evening and will receive positive airway pressure education, hands on demonstration, careful mask fitting and acclimatization prior to titration. The goal during the titration will be to determine the optimal CPAP pressure setting that eliminates obstructive respiratory events, restore oxygen saturations and sleep continuity.~________________________________________

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo tablet
Study: NCT05576051

Intervention type: OTHER
Intervention: patterns of use of combination therapy and monotherapy
Study: NCT02053389

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written decision aid
Description: A written decision aid entitled Making the Choice: Deciding What to Do About Early Stage Prostate Cancer that describes treatment options for early stage prostate cancer.
Study: NCT01769690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBS stimulator setting alteration
Description: 2 sleep study options Phase I: Participants will undergo 2 sleep studies, one with the stimulator on at the subject's stable, clinically effective settings and one with the stimulator off. the order of the off and on nights will be randomized. Although blinding will be attempted, because of the significant motor effects produced with the on setting, participants may be able to tell when the DBS is OFF. In the second phase, the first sleep study night will be with the stimulator OFF. The order of the HIGH, and LOW frequency nights will be randomized 1:1 and balanced across subjects and will occur on the 2nd and 3rd PSG nights.~Phase II Sleep study evaluation will include three nights of recording: 1) OFF with the stimulator off, 2) HIGH with the stimulator on at the participant's stable and clinically effective settings, and 3) LOW with the stimulator set at a low frequency that uses less energy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality simulator
Description: This virtual pedestrian environment is a measure of real-world street-crossing behavior. This simulation is composed of an elevated platform that simulates a curb at a street-side and 3 monitors (arranged in a semi-circle) on which the subject, while wearing headtracker equipment, views the virtual environment of bidirectional traffic. When the subject deems it is safe to cross the virtual street, he/she steps off the platform/curb, which activates crossing of the street by a cartoon representation of the participant. The speed of street crossing by the cartoon is determined by each individual subject's walking speed, which is measured prior to the test.
Study: NCT02619019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally
Study: NCT05576051

Intervention type: OTHER
Intervention: patterns of use of combination therapy and monotherapy

Intervention type: OTHER
Intervention: patterns of use of combination therapy and monotherapy
Study: NCT03726307

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCreg: 0.5 million cells/kg+SOC
Description: DCreg 0.5 (±0.1) million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide.
Study: NCT01193153

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: monthly by i.m. injection for 15 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone palmitate
Description: 78, 117, 156, 234 mg (50, 75, 100, or 150 mg eq.) monthly by i.m. injection for 15 months
Study: NCT00684528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg daily
Description: 500 mg thrice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 1500 mg daily
Description: 500 mg thrice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Janufer (Janumet)
Description: Titration up to 1500/150 mg daily
Study: NCT00921830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: Each subject will receive single doses of (i) ibuprofen 50 mg suppository (ii) ibuprofen 200 mg suppository and (iii) ibuprofen 200 mg tablet in 3 separate dosing periods. Doses will be administered after an overnight fast.
Study: NCT04008394

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Anti-CD30 CAR T cells
Description: Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.
Study: NCT03097237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wholegrain rye
Description: Cereal products based on wholegrain rye
Study: NCT04244006

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Prefilled Syringe
Description: administration of placebo corresponding to placebo arm
Study: NCT03097237

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refined wheat
Description: Cereal products based on refined wheat
Study: NCT04553835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation (RAS) for schizophrenia patients
Description: A mobile application, metronome beats developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. Schizophrenia patients in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on the weekday basis (a total of 15 sessions) with one session (40 minutes) per weekday.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No RAS for schizophrenia patients
Description: The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
Study: NCT00920296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744
Description: GSK drug
Study: NCT00906035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyridamole 200mg and Aspirin 25mg bid:
Description: All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyridamole 200 mg bid
Description: All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 25 mg bid
Description: All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
Study: NCT01007344

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: flaxseed
Description: 1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: whole wheat flour
Description: 1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
Study: NCT00711542

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous bone marrow-derived progenitor cells
Description: intracoronary infusion of autologous bone marrow-derived progenitor cells isolated from 50 ml bone marrow aspirate

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo medium
Description: intracoronary infusion of placebo medium
Study: NCT04249388

Intervention type: OTHER
Intervention: No Intervention, just observation
Description: No Intervention, just observation
Study: NCT04553835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RAS for at-risk individuals
Description: A mobile application, metronome beats developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. At-risk individuals in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on daily basis (a total of 21 sessions), with one training session (40 minutes) per day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No RAS for at-risk individuals
Description: The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
Study: NCT02619019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Description: Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally
Study: NCT02087917

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HS-25
Description: Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HS-25
Description: Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
Study: NCT02580448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seviteronel
Description: Seviteronel given daily with evening meal in 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seviteronel
Description: Seviteronel given daily with evening meal in 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seviteronel
Description: Seviteronel given daily with evening meal in 28 day cycles
Study: NCT00423254

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PSMA/PRAME
Description: Low dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PSMA/PRAME
Description: high dose
Study: NCT01130818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0492
Description: single ascending doses, oral solution (25 to max. 120 mg/intake, 10 to 200 mg/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0492
Description: single ascending doses, oral solution (25 to max. 120 mg/intake, 10 to 200 mg/mL)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose, oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0492
Description: single dose, solid formulation, 50 mg (2\*25 mg/capsule), fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0492
Description: single dose, solid formulation, 50 mg (2\*25 mg/capsule), after high fat breakfast
Study: NCT00789919

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delivery of infant
Description: Vaginal delivery or cesarean section, whichever is indicated
Study: NCT02883088

Intervention type: PROCEDURE
Intervention: Frequency Domain - Optical Coherence Tomography (FD-OCT)
Description: FD-OCT assessment of the native proximal-mid left descending artery during clinically indicated coronary angiography
Study: NCT04104789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kovanaze Nasal Spray
Description: Intra-nasal local anesthetic
Study: NCT02619019

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
Study: NCT04005820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiologic Centralized Review
Description: The patient's imaging will be examined in one of the examination centers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue sample (tumor, sung, urine)
Description: all the samples will be made during the patients care
Study: NCT03451864

Intervention type: PROCEDURE
Intervention: Vaginal delivery
Description: classic vaginal delivery

Intervention type: PROCEDURE
Intervention: Vaginal delivery
Description: classic vaginal delivery

Intervention type: PROCEDURE
Intervention: Cesarean Section
Description: routine lower segment cesarean scetion

Intervention type: PROCEDURE
Intervention: Cesarean Section
Description: routine lower segment cesarean scetion
Study: NCT04158908

Intervention type: BEHAVIORAL
Intervention: Oncolo-GIST
Description: Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topic covered include:~1. Principles of introducing prognosis in the setting of worsened scan results~2. Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months... with emphasizing that the oncology team will always provide care for you)~3. Addressing informational needs and psychological reactions~4. Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith.

Intervention type: BEHAVIORAL
Intervention: Oncolo-GIST
Description: Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topic covered include:~1. Principles of introducing prognosis in the setting of worsened scan results~2. Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months... with emphasizing that the oncology team will always provide care for you)~3. Addressing informational needs and psychological reactions~4. Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith.
Study: NCT03577093

Intervention type: OTHER
Intervention: There is no intervention at all.
Description: There is no intervention at all.

Intervention type: OTHER
Intervention: There is no intervention at all.
Description: There is no intervention at all.
Study: NCT03469154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dyad training method
Description: The training model for paediatric basic life support for laypersons involves a course based on pairs training together guided by instructional videos and with hands-on practice on resuscitation manikins.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instructor led training method
Description: The training model for paediatric basic life support for laypersons involves a course led by an instructor including hands-on practice on resuscitation manikins.
Study: NCT02488252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semi-individualised Chinese Medicine treatment
Description: A: Panax ginseng, Atractylodes macrocephala, Pinellia ternate, Pericarpium citri reticulatae, Herba Pogostemonis, Glycyrrhiza uralensis, Rehmannia-6 decoction~B: Cortex magnoliae officinalis, Atractylodes macrocephala, Common Floweringquince Fruit, Common Vladimiria Root, Tsaoko Amomum Fruit, Palmae Fruit, Radixaconiti laterlis perparata, Zingiber officinale Rosc., Glycyrrhiza uralensis, Rehmannia-8 decoction~C: Root of Pilose Asiabell, Astragalus membranaceus, Rehmannia glutinosa, Common Macrocarpium Fruit, Dioscorea opposita , Barbary Wolfberry Fruit, Cortex eucommiae, Chinese Angelica, Glycyrrhiza uralensis~D: Rehmannia-6 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb~E: Rehmannia-8 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine medical care (active comparator)
Description: Angiotensin converting enzyme inhibitor or angiotensin receptor blocker at stable dose